Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGT-264
- Development stage
- Discontinued
- Lead developer
- Regor Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RGT-264 is a small molecule, orally administered, highly potent and selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), also known as mitogen-activated protein kinase kinase kinase kinase 1. HPK1 acts as a negative regulator of immune cell function, particularly in T cells and dendritic cells. By inhibiting HPK1 activity, RGT-264 aims to enhance anti-tumor immune responses, making it a promising candidate for cancer immunotherapy. The drug was initially developed by Shanghai Qilu Ruige Pharmaceutical R&D Co., Ltd., with current development led by Regor Therapeutics Group/Regor Pharmaceuticals Inc. Its primary indication is for the treatment of solid tumors (neoplasms). As of the latest updates in early 2025, RGT-264 has reached Phase 1 clinical trials for advanced solid tumors but has not yet received regulatory approval[1][2][3][4][5].
- Other names
- RGT 264RGT264RGT-264
02
Targets
MAP4K1 (Hematopoietic progenitor kinase 1)
Beyond the preview
Go deeper on RGT-264.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGT-264.